This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Is antibiotic-resistant bacteria a curse or a blessing for Big Pharma?

By Ben Levine for Kapitall.

At the end of April, the World Health Organization (WHO) for the first time ever released a report on the cresting global crisis of antibiotic resistance

Unsurprisingly, decades of willy-nilly antibiotic use for everything from organ transplants and breast implants to runny noses and splinters has given rise to antibiotic-resistant “superbugs.” And the problem isn't specific to hostpitals or humans:  80 percent of annual antibiotic use in the United States is on animals.

Naturally, the tone of the WHO’s report was particularly dire. As WHO Assistant Director-General for Health Security Dr. Keiji Fukuda put it, “Without urgent, coordinated action by many stakeholders, the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill.” The report mainly focuses on a few problem strains, ones responsible for bloodstream infections, diarrhea, pneumonia, urinary tract infections and gonorrhea. It also breaks down the most pressing antibiotic-resistance concerns geographically, listing E. coli and the bacteria responsible for pneumonia and Staph infections as the primary concerns in the Americas and Europe.

Unfortunately, most of the power and resources for the development of next-generation antibiotics is in the hands of major pharmaceutical companies, and, compared with long-term treatments, antibiotic development isn’t very profitable. Antibiotics are expensive and hard to develop, difficult to get approved by the FDA, and are generally only prescribed for relatively short periods of time. What’s more, the FDA has only approved four new antibiotics in the past 16 years. When earning potential is the only driver of biomedical innovation, new antibiotics don’t get developed.

Yet, gloom and doom aside, there may be a silver lining here. In 2010, the United States’ Biomedical Advanced Research and Development Authority (BARDA) created a program called Broad Spectrum Antimicrobials (BSA). The program engages in public-private partnerships, effectively funding big pharmaceutical companies to develop new antibiotics (because they wouldn’t do it otherwise), giving these companies marketing rights should they develop a product that gains FDA approval. The upshot is that if any of these companies are successful, they stand to make a substantial amount of money. So far, BARDA has created six of these partnerships, with GlaxoSmithKline ( GSK), Achaogen ( AKAO), Cempra ( CEMP), Basilea (OTC:BPMUF), Tetraphase ( TTPH) and Rempex, a subsidiary of The Medicines Company ( MDCO).

The EU followed suit in 2012, creating a program called the Innovative Medicines Initiative that operates in a similar way. The initiative has five pharmaceutical partners so far, two of which are our BSA friends Basilea and GlaxoSmithKline, and the others are Sanofi ( SNY), AstraZeneca ( AZN) and Janssen, a subsidiary of Johnson & Johnson ( JNJ). 

As of yet, there hasn’t been much news that an antibacterial superhero is around the corner, but that’s not to say there isn’t—with the lucrative possibilities of government-funded development, Big Pharma is likely keeping mum.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs